Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Unmutated IGHV at diagnosis in patients with early stage CLL independently predicts for shorter follow-up time to first treatment (TTFT).
Galieni P, Troiani E, Picardi P, Angelini M, Mestichelli F, Dalsass A, Maravalle D, Camaioni E, Bigazzi C, Caraffa P, Ruggieri M, Mazzotta S, Mattioli S, Angelini S. Galieni P, et al. Among authors: caraffa p. Leuk Res. 2024 Aug;143:107541. doi: 10.1016/j.leukres.2024.107541. Epub 2024 Jun 13. Leuk Res. 2024. PMID: 38905908
The detection of circulating plasma cells may improve the Revised International Staging System (R-ISS) risk stratification of patients with newly diagnosed multiple myeloma.
Galieni P, Travaglini F, Vagnoni D, Ruggieri M, Caraffa P, Bigazzi C, Falcioni S, Picardi P, Mazzotta S, Troiani E, Dalsass A, Mestichelli F, Angelini M, Camaioni E, Maravalle D, Angelini S, Pezzoni V. Galieni P, et al. Among authors: caraffa p. Br J Haematol. 2021 May;193(3):542-550. doi: 10.1111/bjh.17118. Epub 2021 Apr 1. Br J Haematol. 2021. PMID: 33792026 Clinical Trial.
Modified BEAM as conditioning regimen for lymphoma patients undergoing autologous hematopoietic stem cell transplantation.
Galieni P, Troiani E, Bigazzi C, Mazzotta S, Ruggieri M, Pezzoni V, Dalsass A, Mestichelli F, Caraffa P, Travaglini F, Ferretti S, Angelini M, Angelini S, Falcioni S. Galieni P, et al. Among authors: caraffa p. Bone Marrow Transplant. 2018 Jan;53(1):91-93. doi: 10.1038/bmt.2017.206. Epub 2017 Oct 2. Bone Marrow Transplant. 2018. PMID: 28967898 No abstract available.
Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study.
Offidani M, Corvatta L, Maracci L, Liberati AM, Ballanti S, Attolico I, Caraffa P, Alesiani F, Caravita di Toritto T, Gentili S, Tosi P, Brunori M, Derudas D, Ledda A, Gozzetti A, Cellini C, Malerba L, Mele A, Andriani A, Galimberti S, Mondello P, Pulini S, Coppetelli U, Fraticelli P, Olivieri A, Leoni P. Offidani M, et al. Among authors: caraffa p. Blood Cancer J. 2013 Nov 22;3(11):e162. doi: 10.1038/bcj.2013.58. Blood Cancer J. 2013. PMID: 24270324 Free PMC article.
Assessment of vulnerability measures and their effect on survival in a real-life population of multiple myeloma patients registered at Marche Region Multiple Myeloma Registry.
Offidani M, Corvatta L, Polloni C, Centurioni R, Visani G, Brunori M, Gentili S, Catarini M, Samori A, Blasi N, Alesiani F, Caraffa P, Burattini M, Galieni P, Fraticelli P, Ferranti M, Giuliodori L, Leoni P. Offidani M, et al. Among authors: caraffa p. Clin Lymphoma Myeloma Leuk. 2012 Dec;12(6):423-32. doi: 10.1016/j.clml.2012.06.008. Epub 2012 Sep 14. Clin Lymphoma Myeloma Leuk. 2012. PMID: 22981966
Phase II study of melphalan, thalidomide and prednisone combined with oral panobinostat in patients with relapsed/refractory multiple myeloma.
Offidani M, Polloni C, Cavallo F, Liberati AM, Ballanti S, Pulini S, Catarini M, Alesiani F, Corvatta L, Gentili S, Caraffa P, Boccadoro M, Leoni P, Palumbo A. Offidani M, et al. Among authors: caraffa p. Leuk Lymphoma. 2012 Sep;53(9):1722-7. doi: 10.3109/10428194.2012.664844. Epub 2012 Mar 16. Leuk Lymphoma. 2012. PMID: 22335534 Clinical Trial.
Thalidomide, dexamethasone, Doxil and Velcade (ThaDD-V) followed by consolidation/maintenance therapy in patients with relapsed-refractory multiple myeloma.
Offidani M, Corvatta L, Polloni C, Gentili S, Mele A, Rizzi R, Catarini M, Caraffa P, Samori A, Blasi N, Ferranti M, Malerba L, Brunori M, Leoni P. Offidani M, et al. Among authors: caraffa p. Ann Hematol. 2011 Dec;90(12):1449-56. doi: 10.1007/s00277-011-1217-0. Epub 2011 Mar 25. Ann Hematol. 2011. PMID: 21437586 Clinical Trial.